UF Health Cancer Center at ASH 2021

American Society of Hematology logo. (PRNewsFoto/American Society of Hematology)

The UF Health Cancer Center will be presenting at the American Society of Hematology (ASH) Annual Meeting that will be held virtually and in-person in-person in Atlanta, Georgia on Dec. 11-14, 2021.

The ASH Annual Meeting is the most comprehensive hematology event of the year. The meeting will provide an invaluable educational experience and overview of the latest scientific highlights in hematology. ASH is a great opportunity for hematology/oncology researchers to engage with your colleagues and network with more than 25,000 hematology professionals from every sub-specialty.

The full conference program is available here.

UF at ASH 2021

All University of Florida Presenters

Oral Presentations

Friday, Dec. 10

Blood Buddies: PhD/ Lab & Translational Hematology (virtual)
Panelists include: Jorg Bungert, Ph.D.
12:30 p.m.-5 p.m.

Blood Buddies: PhD/ Lab & Translational Hematology (in-person)
Panelists include: Jorg Bungert, Ph.D.
1:30 p.m.-2 p.m.

Saturday, Dec. 11

Career Development Lunch: PhD Careers
Presenters include: Olga A Guryanova, M.D., Ph.D.
11:15 a.m.-12:15 p.m.

Sunday, Dec. 12

Announcement of Awards: ASH Mentor Awards
Awardees include: Jonathan Licht, M.D.
1:30 p.m.-2:00 p.m.

Monday, Dec. 13

908 Pharmacogenomics of Fludarabine in Pediatric HCT Recipients: Preliminary Results
Thomas Murphy Ballroom 3-4 (Georgia World Congress Center)
Presenters include: Biljana N. Horn, M.D. and Jatinder K. Lamba, Ph.D.
6:30 p.m.

Poster Presentations

Saturday, Dec. 11

1149 Functional CRISPR Screening Identifies Ptprg As a Driver of Migration and Adhesion in NSD2-E1099K ALL
Authors Include: Charlotte L Kaestner, BS, Amin Sobh, Ph.D., Jianping Li, M.D., Alberto Riva, Ph.D., Richard Lynn Bennett, Ph.D. and Jonathan D. Licht, M.D.
5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)

1227 Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial
5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
Elie Traer, MD, PhD, Ying Huang, MS, MA, Alice S. Mims, MD, Eytan M. Stein, MD, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Martha L. Arellano, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark R. Litzow, MD, Tara L. Lin, MD, Prapti Patel, MD, Matthew C. Foster, MD, Robert L. Redner, MD, Zeina Al-Mansour, M.D., Christopher R. Cogle, M.D., Michael M. Boyiadzis, MD, Ronan Swords, MD PhD, Robert H. Collins, MD, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, PhD RPh, Ashley O. Yocum, PhD, Sonja Marcus, MPH, Timothy Chen, PhD, Franchesca Druggan, MSc, Mona Stefanos, MBChB, Theophilus J Gana, MD PhD, Abigail B. Shoben, PhD, Brian J. Druker, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Uma Borate, MD

1279 Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
Vu H. Duong, MD, Amy S. Ruppert, PhD, Alice S. Mims, MD, Uma Borate, MD, Eytan M. Stein, MD, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William G. Blum, MD, Martha L. Arellano, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, MS, James M. Foran, MD, Mark R. Litzow, MD, Tara L. Lin, MD, Prapti A. Patel, MD, Matthew C. Foster, MD, Robert L. Redner, MD, Zeina Al-Mansour, M.D., Christopher R. Cogle, M.D., Ronan T. Swords, MD, Robert H. Collins, MD22, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, PhD RPh, Ashley O. Yocum, PhD, Sonja Marcus, MPH, Timothy Chen, PhD, Franchesca Druggan, MSc, Mona Stefanos, MBChB, Theophilus J Gana, MD PhD, Abigail B. Shoben, PhD, Brian J. Druker, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Michael M. Boyiadzis, MD

1290 Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant
5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
Vivek M. Shastri, PhD, Tiffany A. Hylkema, BS, Mohammed O Gbadamosi, BS, Soheil Meshinchi, MD, PhD and Jatinder K. Lamba, Ph.D.

1586 Adenylate Kinase 2 Is a Selective Multiple Myeloma Cell Dependency That Is Preferentially Essential in NSD2-Overexpressing Cells
5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
Amin Sobh, PhD, Charlotte L Kaestner, BS, Jianping Li, MD, Alberto Riva, PhD, Richard Lynn Bennett, Ph.D. and Jonathan D. Licht, M.D.

1589 Functional Oncogenomic and Immune Response Landscape for Genes Recurrently Mutated in Myeloma
5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
Ricardo De Matos Simoes, PhD, Benjamin G Barwick, PhD, Ryosuke Shirasaki, MD, Olga Dashevsky, PhD, Sara Gandolfi, MD, PhD, Huihui Tang, PhD, Brian Glassner, PhD, Richard W.J. Groen, PhD, Daniel Auclair, PhD, Aedin Culhane, PhD, Aviad Tsherniak, PhD, Francisca Vazquez, Phd, Jonathan D. Licht, M.D., Lawrence H. Boise, PhD and Constantine S. Mitsiades, MD, PhD

1612 Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma
5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
Olga Dashevsky, PhD, Ricardo De Matos Simoes, PhD, Benjamin G Barwick, PhD, Sara Gandolfi, MD, PhD, Ryosuke Shirasaki, MD, Michal Sheffer, PhD, Aedin Culhane, PhD, Richard WJ Groen, Aviad Tsherniak, PhD, Francisca Vazquez, Phd, Jonathan D. Licht, M.D., Lawrence H. Boise, PhD and Constantine S. Mitsiades, MD, PhD

1772 The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor’s Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201
5:30 PM-7:30 PM
Hall B5 (Georgia World Congress Center)
Nosha Farhadfar, M.D., Stephanie Bo-Subait, MPH, Kwang Woo Ahn, PhD, Brent R. Logan, PhD, Heather E. Stefanski, MD, PhD, Jack W. Hsu, M.D., Sandhya R. Panch, Dennis L. Confer, MD, Claudio Anasetti, MD, Michael A. Pulsipher, MD, Bronwen E. Shaw, MD, PhD, John R. Wingard, M.D. and Galen E. Switzer, PhD

Sunday, Dec. 12

426 Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥60 Years) Hematopoietic Cell Transplant (HCT) Patients
9:30 AM-11:00 AM
B207-B208 (Georgia World Congress Center)
Zeina Al-Mansour, M.D., Sanghee Hong, MD, Nosha Farhadfar, M.D., Jing Zhao, MS, Ji-Hyun Lee, Ph.D., Bronwen E. Shaw, MD, PhD, Steven Devine, MD, Jean C. Yi, PhD, Jaime M. Preussler, MS K. Scott Baker, MD, MS, Karen Syrjala, PhD, Navneet S. Majhail, MD and John R. Wingard, M.D.

2151 DNMT3A with Leukemia-Associated R882 Mutations Promotes Fitness Advantage through Functional Heterogeneity within HSCs
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Zachary Zaroogian, Chamara Gunaratne, BS, Daniil Shabashvili, PhD, Cassandra Berntsen, MS, Yang Feng, BS, MS, Kartika Venugopal, PhD, Santhi Pondugula, PhD and Olga A Guryanova, M.D., Ph.D.

2161 Dnmt3a Mutations in the Hematopoietic System Promote Colitis-Associated Colon Cancer: A Model of Clonal Hematopoiesis in Solid Tumors
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Yang Feng, BS, MS, Rachel Newsome, Troy Robinson, Robert L. Bowman, PhD, Ashley Zuniga, PhD, Kendra Hall, Cassandra Bernsten, MS, Daniil Shabashvili, PhD, Kathryn Krajcik, Chamara Gunaratne, BS, Zachary Zaroogian, Kartika Venugopal, PhD, Heidi Casellas Roman, MS, Ross L. Levine, MD, Alberto Riva, PhD, Daniel Kopinke, PhD, Christian Jobin, Ph.D., Dorina Avram, PhD and Olga A Guryanova, M.D., PhD

2230 Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Yannan Jia, Qi Zhang, PhD, Weiguo Zhang, MD, PhD, Michael Andreeff, MD, PhD, Nitin Jain, MD, Peiyi Zhang, MS, Guangrong Zheng, Ph.D., Daohong Zhou, M.D., and Marina Konopleva, MD, PhD

2247 The rs35112940 CD33 Polymorphism Reduces CD33 Internalization and Efficacy of CD33-Directed Gemtuzumab Ozogamicin
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Mohammed O Gbadamosi, BS, Vivek M. Shastri, PhD, Soheil Meshinchi, MD, PhD and Jatinder K. Lamba, Ph.D.

2252 Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Daisy Diaz Rohena, BS, Janani Ravikrishnan, BS, Chaomei Liu, Guangrong Zheng, Ph.D., Daohong Zhou, M.D., Peiyi Zhang, MS, William G. Wierda, Nitin Jain, MD, Jennifer A. Woyach, MD and Deepa Sampath, PhD

2304 Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children’s Oncology Group (COG) Study AALL1731
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Amanda M. Li, MD, Karen R Rabin, MD, PhD, John Kairalla, Ph.D., Cindy Wang, MS, Meenakshi Devidas, PhD, MBA, Olga Militano, PharmD, Maki Okada, RN, Johann K Hitzler, MD, Anne L Angiolillo, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Sumit Gupta, MD and Rachel E. Rau, MD

2373 Pharmacogenomics to Predict Mucositis in Acute Myeloid Leukemia
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Jennifer Ahmed, PharmD, Leila Becirevic, Natasha Emanuel, PharmD, Molly E. Lofy, Hanh Tran, Vivek M. Shastri, PhD and Jatinder K. Lamba, Ph.D.

2382 Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children’s Oncology Group Report
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Natalie Delrocco, Mignon L. Loh, MD, Michael Borowitz, MD, PhD, Karen R Rabin, MD, PhD, Patrick A Zweidler-McKay, MD, PhD, Kelly W Maloney, MD6, Leonard A. Mattano, MD, Eric C Larsen, MD, Anne L Angiolillo, MD, Reuven J Schore, MD, Michael J. Burke, MD, Wanda L Salzer, MD, Brent L. Wood, MD, PhD, Andrew J Carroll, PhD, Nyla A. Heerema, PhD, Shalini C Reshmi, PhD, Julie M Gastier-Foster, PhD, Richard C Harvey, PhD, I-Ming L Chen, Kathryn G Roberts, PhD, Charles G. Mullighan, MBBS, MD, Cheryl L Willman, MD, Naomi J Winick, MD, William L. Carroll, MD, Stephen P. Hunger, MD, Elizabeth A. Raetz, MD, Meenakshi Devidas, PhD and John Kairalla, Ph.D.

2849 Paper: Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment – a Post-Hoc Analysis of the Genesis Trial
6:00-8:00 PM
Hall B5 (Georgia World Congress Center)
Zachary D. Crees, MD, Keith E. Stockerl-Goldstein, MD, Michael Retting, PhD, Sarah M Larson, MD, Arpad Illes, MD, PhD, Giuseppe Milone, MD, Prof, Massimo Martino, Patrick Stiff, MD, Douglas W. Sborov, MD, MS, Denise L. Pereira, MD, Ivana N. Micallef, MD, Gemma Moreno Jiménez, MD, Gábor Mikala, MD, PhD, Maria Liz Paciello Coronel, Udo Holtick, MD, PhD, John W. Hiemenz, M.D., Muzaffar H. Qazilbash, MD, Nancy M. Hardy, MD, Tahir Latif, MD, Irene García-Cadenas, MD, Ella Sorani, PhD, Liron Shemesh-Darvish, PhD, Abi Vainstein, MD, Shaul Kadosh and John F. DiPersio, MD, PhD

475 Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial
Hall A1 (Georgia World Congress Center)
12:00-1:30 PM
Zachary D. Crees, MD, Keith E. Stockerl-Goldstein, MD, Sarah Larson, MD, Árpád Illés, Giuseppe Milone, MD, Prof, Massimo Martino, Patrick Stiff, MD, Douglas W. Sborov, MD, MS, Denise L. Pereira, MD, Ivana N. Micallef, MD, Gemma Moreno Jiménez, MD, Gábor Mikala, MD, PhD, Maria liz paciello Coronel, Udo Holtick, MD, PhD, John W. Hiemenz, M.D., Muzaffar H. Qazilbash, MD, Nancy M. Hardy, MD, Tahir Latif, MD, Irene García-Cadenas, MD, Abi Vainstein, MD, Ella Sorani, PhD, Irit Gliko-Kabir, Inbal Goldstein, Shaul Kadosh and John F. DiPersio, MD, PhD

Monday, Dec. 13

875 Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial
Thomas Murphy Ballroom 1-2 (Georgia World Congress Center)
6:15 PM-7:45 PM
Prapti Patel, MD, Amy S. Ruppert, PhD, Uma Borate, MD, Eytan M. Stein, MD, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Martha L. Arellano, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark R. Litzow, MD, Tara L. Lin, MD, Matthew C. Foster, MD, Robert L. Redner, MD, Zeina Al-Mansour, M.D., Christopher R. Cogle, M.D., Michael M. Boyiadzis, MD, Ronan Swords, MD PhD, Robert H. Collins, MD, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, PhD RPh, Ashley Owen Yocum, PhDSonja Marcus, MPH, Timothy Chen, PhD, Franchesca Druggan, MS, Mona Stefanos, MBChB, Theophilus J Gana, MD PhD, Abigail B. Shoben, PhD, Brian J. Druker, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Alice S. Mims, MD

907 Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia – CIBMTR Analysis
Thomas Murphy Ballroom 3-4 (Georgia World Congress Center)
6:15 PM-7:45 PM
Guru Subramanian Guru Murthy, MD, Brent R. Logan, PhD, Stephanie Bo-Subait, MPH, Amer Beitingjaneh, Steven Devine, MD, Nosha Farhadfar, M.D., Lohith Gowda, MD, Shahrukh Hashmi, MD, MPH, Hillard Lazarus, Sunita Nathan, MD, Akshay Sharma, MBBS, Jean A. Yared, MD, Heather E. Stefanski, MD, PhD, Michael A. Pulsipher, MD, Jack W. Hsu, M.D., Galen E. Switzer, PhD, Sandhya R. Panch and Bronwen E. Shaw, MD, PhD

3360 Pharmacogenomic Single Nucleotide Polymorphism (SNP) Variants As Predictors of Toxicity Phenotypes in the Treatment of Acute Childhood Leukemia
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Reema Kashif, MD, Trisha Larkin, MD, MBA, Abdelrahman H Elsayed, MS, Nam H.K. Nguyen, PharmD/MS, Natasha Emanuel, PharmD, Vivek M. Shastri, PhD, Roya Rafiee, MS, PhD, Karna Mangrola, DO3, Biljana N. Horn, M.D. and Jatinder K. Lamba, Ph.D.

3415 Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Justin M Watts, MD, Tara L. Lin, MD, Alice S. Mims, MD, Prapti Patel, MD, Paul J Shami, MD, Elizabeth H. Cull, MD, Christopher R. Cogle, M.D., Cynthia Lee, PhD and Fatih Uckun, MD, PhD

3416 Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Tara L. Lin, MD, Justin M Watts, MD, Alice S. Mims, MD, Prapti Patel, MD, Paul J Shami, MD, Elizabeth H. Cull, MD, Christopher R. Cogle, M.D., Cynthia Lee, PhD and Fatih Uckun, MD, PhD

3429 Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Richard J Marrero, PharmD, Abdelrahman H Elsayed, MS, Xueyuan Cao, Huiyun Wu, PhD, Lei Wang, MS, Raul C Ribeiro, MD, Jeffrey E. Rubnitz, MD, Stanley B Pounds, PhD and Jatinder K. Lamba, Ph.D.

3456 A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Vivek M. Shastri, PhD, Lata Chauhan, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, MS, Richard Aplenc, MD, PhD, Betsy A Hirsch, PhD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD and Jatinder K. Lamba, Ph.D.

3812 Direct Intravital Imaging of the Bone Marrow and Splenic Hematopoietic Niches in Individual Mice to Define the Early Engraftment Kinetics Following HSC-Transplant
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Augustine Vinson, Alexander Ligocki, Christopher R. Cogle, M.D. and Edward Scott, Ph.D.

3932 Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Nosha Farhadfar, M.D., Michael Weaver, Ph.D., Zeina Al-Mansour, M.D., Jean C. Yi, PhD, Heather S. L. Jim, PhD, Alison W. Loren, MD, Navneet S. Majhail, MD, Victoria Whalen, BS, John R. Wingard, M.D., Debra Lynch Kelly, Ph.D. and Karen Syrjala, PhD

4123 Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Sanghee Hong, MD, Jing Zhao, MS, Ji-Hyun Lee, PhD, Nosha Farhadfar, M.D., Jean C. Yi, PhD, Jaime M. Preussler, MS, K. Scott Baker, MD MS, Bronwen E. Shaw, MD, PhD, Steven Devine, MD, Karen Syrjala, PhD, John R. Wingard, M.D., Navneet S. Majhail, MD and Zeina Al-Mansour, M.D.

3297 Dysregulation of Epigenetic Landscape Uncovered the Mechanisms Underlying the Relapse of Pediatric Acute Lymphoblastic Leukemia with NSD2 Mutation
Hall B5 (Georgia World Congress Center)
6:00 PM-8:00 PM
Jianping Li, MD, Priscillia Lhoumaud, PhD, Alberto Riva, PhD, Crissandra Piper, LATG, Daphne Dupere-Richer, PhD, Heidi Casellas Roman, MS, Amin Sobh, PhD, Charlotte L Kaestner, BS, Alok Swaroop, PhD, Marta Kulis, PhD, Richard Lynn Bennett, Ph.D., Jane Skok, PhD and Jonathan D. Licht, M.D.

NCI Cancer Center badge